BDBM135819 US10085990, Example 103::US10568888, Example 103::US8853226, 103::US9393245, 103

SMILES COc1cccc2c1ncc1c2n(C2CC[C@@H](CC2)C(O)=O)c(=O)n(-c2cccc(Cl)c2)c1=O

InChI Key InChIKey=VLSIAPYZDCCBPU-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 135819   

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 17nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2015
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 55nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2015
Entry Details
Go to US Patent

TargetTumor necrosis factor(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 1nMT: 2°CAssay Description:Add 100 μL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. Cover with an adhesive strip and incubate 2 hours at ro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 17nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 55nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 17nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 55nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 17nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 55nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent